Aradigm Corporation  

(Public, NASDAQ:ARDM)   Watch this stock  
Find more results for OTC:ARDM
7.66
-0.04 (-0.47%)
Jan 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.50 - 7.96
52 week 6.43 - 15.96
Open 7.96
Vol / Avg. 11,547.00/9,001.00
Mkt cap 111.14M
P/E 23.36
Div/yield     -
EPS 0.33
Shares 14.71M
Beta 0.76
Inst. own 36%
Mar 23, 2015
Q4 2014 Aradigm Corp Earnings Release (Estimated) Add to calendar
Feb 10, 2015
Aradigm Corp at Biotechnology Industry Organization CEO & Investor Conference - 2:30PM EST - Add to calendar
Jan 14, 2015
Aradigm Corp at EBD Biotech Showcase
Nov 7, 2014
Q3 2014 Aradigm Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -13.81% -221.92%
Operating margin -13.25% -204.92%
EBITD margin - -36.76%
Return on average assets -6.70% -72.62%
Return on average equity -9.14% -133.76%
Employees 12 -
CDP Score - -

Address

3929 Point Eden Way
HAYWARD, CA 94545
United States - Map
+1-510-2659000 (Phone)
+1-510-2658878 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases. The Company invested its capital to develop drug delivery technologies, particularly the development of pulmonary (respiratory) drug delivery as incorporated in its lead product candidate entering Phase III clinical trials, Pulmaquin. The Company has also invested in the generation of a large volume of laboratory and clinical data demonstrating the performance of its AERx pulmonary drug delivery platform and other proprietary technologies, including its inhaled ciprofloxacin formulations. The key technologies the Company has focused its efforts on are inhaled ciprofloxacin formulations and nicotine inhaler for smoking cessation.

Officers and directors

Virgil D. Thompson Independent Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Igor Gonda Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Nancy E. Pecota Chief Financial Officer, Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Juergen Froehlich M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
David Bell Independent Director
Age: 59
Bio & Compensation  - Reuters
Lafmin Morgan Independent Director
Age: 49
Bio & Compensation  - Reuters
Helen E. Short Independent Director
Age: 64
Bio & Compensation  - Reuters
John M. Siebert Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters